Pantoprazole 20/40 mg in Reflux-Associated Complaints With Focus on Gastrointestinal Symptoms.

Trial Profile

Pantoprazole 20/40 mg in Reflux-Associated Complaints With Focus on Gastrointestinal Symptoms.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2014

At a glance

  • Drugs Pantoprazole (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Acronyms PARADE
  • Sponsors Takeda Pharmaceuticals International GmbH
  • Most Recent Events

    • 07 May 2012 Company (Takeda Pharmaceuticals International GmbH) added in the association field as reported by ClinicalTrials.gov.
    • 07 May 2012 Additional lead trial centre (Takeda Pharmaceuticals International GmbH) identified as reported by ClinicalTrials.gov.
    • 07 May 2012 Company (Takeda Global Research and Development Center) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top